Peizer Terren S's Form 4 filing
Biovie Inc.BIVI · filed Aug 26, 2022
- Accession no.
- 0001520138-22-000381
- Filed
- Aug 26, 2022, 5:10 PM ET
- Trade date
- Jul 3, 2018-Jun 10, 2021
- Filing delay
- 1,515 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions and 10 derivative transactions. It was filed 1515 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Peizer Terren SCIK 0000904534 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2018 | Common Stock | CConversionAcquired | +1,600,000 | –F1 | – | 1,600,000 | Indirect | |
| Jan 2, 2019 | Common Stock | AGrant or awardAcquired | +1,600 | $0.00 | $0 | 1,601,600 | Direct | |
| Jun 24, 2019 | Common Stock | AGrant or awardAcquired | +1,526,334 | $45.00 | +$68,685,030 | 3,127,934 | Indirect | |
| Sep 24, 2019 | Common Stock | AGrant or awardAcquired | +1,125,000 | –F6 | – | 4,252,934 | Indirect | |
| Jan 2, 2020 | Common Stock | AGrant or awardAcquired | +4,422 | –F7 | – | 4,257,356 | Indirect | |
| Jan 2, 2020 | Common Stock | AGrant or awardAcquired | +1,600 | $0.00 | $0 | 4,258,956 | Direct | |
| Sep 22, 2020 | Common Stock | AGrant or awardAcquired | +5,359,832 | –F8 | – | 9,618,788 | Indirect | |
| Sep 22, 2020 | Common Stock | MOption exerciseAcquired | +1,549,750 | $0.0001 | +$154.98 | 11,168,538 | Indirect | |
| Jun 10, 2021 | Common Stock | AGrant or awardAcquired | +8,361,308 | –F9 | – | 19,529,846 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2018 | Common Stock | PPurchaseAcquired | +1,600,000 | –F10 | – | 1,600,000 | Indirect | |
| Jul 3, 2018 | Common Stock | PPurchaseAcquired | +1,713,331 | –F10 | – | 1,713,331 | Indirect | |
| Aug 3, 2018 | Common Stock | CConversionDisposed | −1,600,000 | –F10 | – | 0 | Indirect | |
| Jun 24, 2019 | Common Stock | DReturned to the companyDisposed | −1,713,331 | –F5 | – | 0 | Indirect | |
| Sep 24, 2019 | 10% Convertible Debenture due 2020 | AGrant or awardAcquired | – | –F6 | – | – | Indirect | |
| Sep 24, 2019 | Common Stock | AGrant or awardAcquired | +1,250,000 | –F6 | – | 1,250,000 | Indirect | |
| Jul 13, 2020 | Common Stock | AGrant or awardAcquired | +299,750 | –F6 | – | 299,750 | Indirect | |
| Sep 22, 2020 | 10% Convertible Debenture due 2020 | DReturned to the companyDisposed | – | $0.00 | – | 0 | Indirect | |
| Sep 22, 2020 | Common Stock | MOption exerciseDisposed | −1,250,000 | –F8 | – | 0 | Indirect | |
| Sep 22, 2020 | Common Stock | MOption exerciseDisposed | −299,750 | –F8 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
See Exhibit 99.1
Referenced by the price of 1 transaction in Table I.
- F5
Pursuant to a letter agreement with the Issuer dated June 24, 2019, Acuitas agreed to modify its existing rights under the 2018 SPA and agreed to immediately exchange the 2018 Warrants such that it effectively exercised its warrant in full pursuant to a cashless exercise thereof at an assumed then-current market price of $45 per share (adjusted to reflect the Reverse Stock Split) and, as a result, received an aggregate of 95% of the shares covered thereby.
Referenced by the price of 1 transaction in Table II.
- F6
See Exhibit 99.1
Referenced by the price of 1 transaction in Table I and 3 transactions in Table II.
- F7
The Issuer paid $13,487 of accrued interest on the Debenture through the issuance of 4,422 shares of the Issuer's common stock to Acuitas.
Referenced by the price of 1 transaction in Table I.
- F8
See Exhibit 99.1
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.
- F9
The Issuer issued these shares to NeurMedix, Inc. ("NeurMedix") in partial consideration for the acquisition of certain assets from NeurMedix and the assumption of certain liabilities of NeurMedix pursuant to the Asset Purchase Agreement, dated April 27, 2021, by and among the Issuer, NeurMedix, Inc. and Acuitas. In connection with the closing, NeurMedix assigned the rights to receive such shares to Acuitas.
Referenced by the price of 1 transaction in Table I.
- F10
See Exhibit 99.1
Referenced by the price of 3 transactions in Table II.
Remarks
Exhibit 99.1 - Explanation of Responses